Randomized trial demonstrates reduced tumor burden in bone metastasis with combined DKK1 blockade and zoledronic acid, indicating a new therapeutic approach.
Key Points
This study aims to understand how the DKK1-CKAP4 axis influences myeloid cell functions in the bone tumor microenvironment and offers new therapeutic strategies against bone metastasis.
Utilized a knockout mouse model to study the DKK1-CKAP4 axis in myeloid cell regulation.
Explored the effects of DKK1 blockade combined with zoledronic acid on the tumor microenvironment.
Validated therapeutic efficacy in bone metastasis mouse models.
Myeloid cell populations significantly expanded in the bone tumor microenvironment.
DKK1-CKAP4 axis altered neutrophil behaviour, leading to an immunosuppressive phenotype and promoted osteoclast-like differentiation.
Combined treatment restored anti-tumor immunity and reduced tumor burden in bone metastatic models.